胰高血糖素样肽-1受体PET/CT定位诊断胰岛素瘤的技术规范

罗亚平; 李方; 于淼; 邢小平; 张太平; 赵玉沛

doi:10.3969/j.issn.1674-9081.2020.04.022

胰高血糖素样肽-1受体PET/CT定位诊断胰岛素瘤的技术规范

doi: 10.3969/j.issn.1674-9081.2020.04.022

罗亚平^{1, 2},
李方^{1, 2, ,},
于淼³,
邢小平³,
张太平⁴,
赵玉沛⁴

1.
中国医学科学院北京协和医学院北京协和医院核医学科, 北京 100730
2.
核医学分子靶向诊疗北京市重点实验室, 北京 100730
3.
中国医学科学院北京协和医学院北京协和医院内分泌科, 北京 100730
4.
中国医学科学院北京协和医学院北京协和医院基本外科, 北京 100730

基金项目:

国家自然科学基金 81501515

公益性行业科研专项 201402001

详细信息

通讯作者:
李方电话:010-69155502, E-mail:lifang@pumch.cn

中图分类号: R587;R445
计量
- 文章访问数: 501
- HTML全文浏览量: 71
- PDF下载量: 166
- 被引次数: 0
出版历程
- 收稿日期: 2018-05-29
- 刊出日期: 2020-07-30

Procedure Guideline of Glucagon-like Peptide-1 Receptor Positron Emission Tomography/Computed Tomography in Localizing Insulinoma

Ya-ping LUO^{1, 2},
Fang LI^{1, 2
, ,},
Miao YU³,
Xiao-ping XING³,
Tai-ping ZHANG⁴,
Yu-pei ZHAO⁴

1.
Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
2.
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China
3.
Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
4.
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

Corresponding author: LI Fang Tel: 86-10-69155502, E-mail:lifang@pumch.cn

摘要

摘要: 胰岛素瘤的诊断和手术治疗依赖于准确的影像学检查定位。以胰腺β细胞为靶点的胰高血糖素样肽-1受体(glucagon-like peptide-1 receptor, GLP-1R)是近年来胰岛素瘤影像研究中的亮点, 推荐临床推广使用⁶⁸Ga-exendin-4进行GLP-1R正电子发射断层显像/计算机体层成像(positron emission tomography/computed tomography, PET/CT)来定位诊断胰岛素瘤。本文介绍GLP-1R显像在胰岛素瘤中的应用概况, 并以⁶⁸Ga-exendin-4 GLP-1R PET/CT显像为例, 介绍该技术的操作规范, 以期为临床提供借鉴。
- 胰高血糖素样肽-1受体 /
- ⁶⁸Ga-exendin-4 /
- 胰岛素瘤 /
- 技术
Abstract: The diagnosis and surgical treatment of insulinoma is dependent on accurate localization with imaging modalities. Glucagon-like peptide-1 receptor (GLP-1R) imaging that targets pancreatic β cells has been highlighted for detecting insulinomas in recent years. Since the high sensitivity and specificity (se. 99%, sp. 100%) of GLP-1R imaging in localizing insulinoma, GLP-1R positron emission tomography/computed tomography (PET/CT) with ⁶⁸Ga-exendin-4 is recommended to be introduced into clinical practice. This paper introduced the application of GLP-1R imaging in insulinoma, and took the GLP-1R PET/CT with ⁶⁸Ga-exendin-4 as an example to elaborate the operation standard of this technique, aiming to provide a reference for clinical practice.
- glucagon-like peptide-1 receptor /
- ⁶⁸Ga-exendin-4 /
- insulinoma /
- technology
注释:

利益冲突 无

HTML全文

图 1 正常⁶⁸Ga-exendin-4 PET/CT最大密度投影图，胰腺可见均匀生理性摄取

下载: 全尺寸图片幻灯片

图 2 胰岛素瘤患者⁶⁸Ga-exendin-4 PET/CT示胰腺钩突部胰岛素瘤⁶⁸Ga-exendin-4摄取异常增高(A、B，白色箭头)，十二指肠可见局灶性摄取轻度增高区(A、C，红色箭头)，胰腺颈、体、尾部可见弥漫均匀生理性摄取(A、C，蓝色箭头)

A.最大密度投影图；B、C.横断层融合图

下载: 全尺寸图片幻灯片

图 3 胰腺钩突部胰岛素瘤患者⁶⁸Ga-exendin-4 PET/CT可见钩突部胰岛素瘤放射性摄取异常增高(A、B，红色箭头), 胰腺颈体尾部见轻度生理性摄取(A，蓝色箭头); 胰岛素瘤肝转移患者⁶⁸Ga-exendin-4 PET/CT可见肝内大量转移灶，放射性摄取异常增高(C、D，红色箭头)，胰腺体尾部胰岛素瘤原发灶摄取明显增高(C、D，蓝色箭头)

A.最大密度投影图；B.横断层融合图；C.最大密度投影图；D.横断层融合图

下载: 全尺寸图片幻灯片

参考文献(36)

[1]	Grant CS. Insulinoma[J]. Best Pract Res Clin Gastroenterol, 2005, 19:783-798. doi: 10.1016/j.bpg.2005.05.008
[2]	Fidler JL, Fletcher JG, Reading CC, et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT[J]. AJR Am J Roentgenol, 2003, 181:775-780. doi: 10.2214/ajr.181.3.1810775
[3]	Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Radiological, Nuclear Medicine & Hybrid Imaging[J]. Neuroendocrinology, 2017, 105:212-244. doi: 10.1159/000471879
[4]	Rostambeigi N, Thompson GB. What should be done in an operating room when an insulinoma cannot be found?[J]. Clin Endocrinol (Oxf), 2009, 70:512-515. doi: 10.1111/j.1365-2265.2009.03527.x
[5]	Sotoudehmanesh R, Hedayat A, Shirazian N, et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma[J]. Endocrine, 2007, 31:238-241. doi: 10.1007/s12020-007-0045-4
[6]	Korner M, Stockli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues:potential for in vivo targeting[J]. J Nucl Med, 2007, 48:736-743. doi: 10.2967/jnumed.106.038679
[7]	Heller RS, Aponte GW. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-36) amide[J]. Am J Physiol, 1995, 269:G852-860.
[8]	Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide Ⅰ receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas[J]. Diabetes, 1997, 46:785-791. doi: 10.2337/diab.46.5.785
[9]	Tornehave D, Kristensen P, Romer J, et al. Expression of the GLP-1 receptor in mouse, rat, and human pancreas[J]. J Histochem Cytochem, 2008, 56:841-851. doi: 10.1369/jhc.2008.951319
[10]	Korner M, Christ E, Wild D, et al. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications[J]. Front Endocrinol (Lausanne), 2012, 3:158. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000003590916
[11]	Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas[J]. Pharmacol Ther, 2007, 113:546-593. doi: 10.1016/j.pharmthera.2006.11.007
[12]	Pauly RP, Demuth HU, Rosche F, et al. Improved glucose tolerance in rats treated with the dipeptidyl peptidase Ⅳ (CD26) inhibitor Ile-thiazolidide[J]. Metabolism, 1999, 48:385-389. doi: 10.1016/S0026-0495(99)90090-2
[13]	Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas[J]. J Biol Chem, 1992, 267:7402-7405.
[14]	Wild D, Wicki A, Mansi R, et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT[J]. J Nucl Med, 2010, 51:1059-1067. doi: 10.2967/jnumed.110.074914
[15]	Wild D, Behe M, Wicki A, et al.[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1(GLP-1) receptor targeting[J]. J Nucl Med, 2006, 47:2025-2033.
[16]	Brom M, Joosten L, Oyen WJ, et al. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas[J]. Contrast Media Mol Imaging, 2012, 7:160-166. doi: 10.1002/cmmi.475
[17]	Wicki A, Wild D, Storch D, et al.[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma[J]. Clin Cancer Res, 2007, 13:3696-3705. doi: 10.1158/1078-0432.CCR-06-2965
[18]	Jodal A, Lankat-Buttgereit B, Brom M, et al. A comparison of three (67/68)Ga-labelled exendin-4 derivatives for beta-cell imaging on the GLP-1 receptor:the influence of the conjugation site of NODAGA as chelator[J]. EJNMMI Res, 2014, 4:31. doi: 10.1186/s13550-014-0031-9
[19]	Gotthardt M, Fischer M, Naeher I, et al. Use of the incretin hormone glucagon-like peptide-1(GLP-1) for the detection of insulinomas:initial experimental results[J]. Eur J Nucl Med Mol Imaging, 2002, 29:597-606. doi: 10.1007/s00259-002-0761-1
[20]	Brom M, Oyen WJ, Joosten L, et al. ⁶⁸Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET[J]. Eur J Nucl Med Mol Imaging, 2010, 37:1345-1355. doi: 10.1007/s00259-009-1363-y
[21]	Kiesewetter DO, Guo N, Guo J, et al. Evaluation of an[(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in Insulinoma[J]. Theranostics, 2012, 2:999-1009. doi: 10.7150/thno.5276
[22]	Wu Z, Todorov I, Li L, et al. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor[J]. Bioconjug Chem, 2011, 22:1587-1594. doi: 10.1021/bc200132t
[23]	Wu Z, Liu S, Hassink M, et al. Development and evaluation of ¹⁸F-TTCO-Cys40-Exendin-4:a PET probe for imaging transplanted islets[J]. J Nucl Med, 2013, 54:244-251. doi: 10.2967/jnumed.112.109694
[24]	Selvaraju RK, Velikyan I, Asplund V, et al. Pre-clinical evaluation of[(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma[J]. Nucl Med Biol, 2014, 41:471-476. doi: 10.1016/j.nucmedbio.2014.03.017
[25]	Wild D, Macke H, Christ E, et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas[J]. N Engl J Med, 2008, 359:766-768. doi: 10.1056/NEJMc0802045
[26]	Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas[J]. J Clin Endocrinol Metab, 2009, 94:4398-4405. doi: 10.1210/jc.2009-1082
[27]	Christ E, Wild D, Ederer S, et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas:a prospective multicentre imaging study[J]. Lancet Diabetes Endocrinol, 2013, 1:115-122. doi: 10.1016/S2213-8587(13)70049-4
[28]	Sowa-Staszczak A, Pach D, Mikolajczak R, et al. Glucagon-like peptide-1 receptor imaging with[Lys40(Ahx-HYNIC- ^99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma[J]. Eur J Nucl Med Mol Imaging, 2013, 40:524-531. doi: 10.1007/s00259-012-2299-1
[29]	Antwi K, Fani M, Nicolas G, et al. Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT:A Pilot Study[J]. J Nucl Med, 2015, 56:1075-1078. doi: 10.2967/jnumed.115.157768
[30]	Luo Y, Yu M, Pan Q, et al. (68)Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake[J]. Eur J Nucl Med Mol Imaging, 2015, 42:531-532. doi: 10.1007/s00259-014-2946-9
[31]	Luo Y, Li N, Kiesewetter DO, et al. ⁶⁸Ga-NOTA-Exendin-4 PET/CT in Localization of an Occult Insulinoma and Appearance of Coexisting Esophageal Carcinoma[J]. Clin Nucl Med, 2016, 41:341-343. doi: 10.1097/RLU.0000000000001087
[32]	Luo Y, Pan Q, Yao S, et al. Glucagon-Like Peptide-1 Receptor PET/CT with ⁶⁸Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma:A Prospective Cohort Study[J]. J Nucl Med, 2016, 57:715-720. doi: 10.2967/jnumed.115.167445
[33]	Luo Y, Li J, Yang A, et al. ⁶⁸Ga-Exendin-4 PET/CT in Evaluation of Endoscopic Ultrasound-Guided Ethanol Abla-tion of an Insulinoma[J]. Clin Nucl Med, 2017, 42:310-311. doi: 10.1097/RLU.0000000000001563
[34]	罗亚平, 潘青青, 要少波, 等.⁶⁸Ga-exendin-4 PET/CT显像定位诊断胰岛素瘤[J].中华核医学与分子影像杂志, 2017, 37:137-141. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhhyx201703004
[35]	Vegt E, Melis M, Eek A, et al. Renal uptake of different radiolabelled peptides is mediated by megalin:SPECT and biodistribution studies in megalin-deficient mice[J]. Eur J Nucl Med Mol Imaging, 2011, 38:623-632. doi: 10.1007/s00259-010-1685-9
[36]	Selvaraju RK, Bulenga TN, Espes D, et al. Dosimetry of[(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human-repeated scanning in human is possible[J]. Am J Nucl Med Mol Imaging, 2015, 5:259-269.

施引文献

资源附件(0)

访问统计

点击查看大图

图(3)

计量

文章访问数: 501
HTML全文浏览量: 71
PDF下载量: 166
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

胰高血糖素样肽-1受体PET/CT定位诊断胰岛素瘤的技术规范

doi: 10.3969/j.issn.1674-9081.2020.04.022

通讯作者:
李方电话:010-69155502, E-mail:lifang@pumch.cn

计量

Procedure Guideline of Glucagon-like Peptide-1 Receptor Positron Emission Tomography/Computed Tomography in Localizing Insulinoma

Corresponding author: LI Fang Tel: 86-10-69155502, E-mail:lifang@pumch.cn

计量

目录

留言板

胰高血糖素样肽-1受体PET/CT定位诊断胰岛素瘤的技术规范

doi: 10.3969/j.issn.1674-9081.2020.04.022

通讯作者: 李方 电话:010-69155502, E-mail:lifang@pumch.cn

计量

出版历程

Procedure Guideline of Glucagon-like Peptide-1 Receptor Positron Emission Tomography/Computed Tomography in Localizing Insulinoma

Corresponding author: LI Fang Tel: 86-10-69155502, E-mail:lifang@pumch.cn

计量

出版历程

目录

通讯作者:
李方电话:010-69155502, E-mail:lifang@pumch.cn